Future Continuous Manufacturing and Advanced Crystallisation Research Hub

Lead Research Organisation: University of Strathclyde
Department Name: Inst of Pharmacy and Biomedical Sci

Abstract

Our Hub research is driven by the societal need to produce medicines and materials for modern living through novel manufacturing processes. The enormous value of the industries manufacturing these high value products is estimated to generate £50 billion p.a. in the UK economy. To ensure international competitiveness for this huge UK industry we must urgently create new approaches for the rapid design of these systems, controlling how molecules self-assemble into small crystals, in order to best formulate and deliver these for patient and customer. We must also develop the engineering tools, process operations and control methods to manufacture these products in a resource-efficient way, while delivering the highest quality materials.

Changing the way in which these materials are made, from what is called "batch" crystallisation (using large volume tanks) to "continuous" crystallisation (a more dynamic, "flowing" process), gives many advantages, including smaller facilities, more efficient use of expensive ingredients such as solvents, reducing energy requirements, capital investment, working capital, minimising risk and variation and, crucially, improving control over the quality and performance of the particles making them more suitable for formulation into final products. The vision is to quickly and reliably design a process to manufacture a given material into the ideal particle using an efficient continuous process, and ensure its effective delivery to the consumer. This will bring precision medicines and other highly customisable projects to market more quickly. An exemplar is the hubs exciting innovation partnership with Cancer Research UK.

Our research will develop robust design procedures for rapid development of new particulate products and innovative processes, integrate crystallisation and formulation to eliminate processing steps and develop reconfiguration strategies for flexible production. This will accelerate innovation towards redistributed manufacturing, more personalisation of products, and manufacturing closer to the patient/customer. We will develop a modular MicroFactory for integrated particle engineering, coupled with a fully integrated, computer-modelling approach to guide the design of processes and materials at molecule, particle and formulation levels. This will help optimise what we call the patient-centric supply chain and provide customisable products. We will make greater use of targeted experimental design, prediction and advanced computer simulation of new formulated materials, to control and optimise the processes to manufacture them.

Our talented team of scientists will use the outstanding capabilities in the award winning £34m CMAC National Facility at Strathclyde and across our 6 leading university spokes (Bath, Cambridge, Imperial, Leeds, Loughborough, Sheffield). This builds on existing foundations independently recognised by global industry as 'exemplary collaboration between industry, academia and government which represents the future of pharmaceutical manufacturing and supply chain R&D framework'.

Our vision will be translated from research into industry through partnership and co-investment of £31m. This includes 10 of world's largest pharmaceutical companies (eg AstraZeneca, GSK), chemicals and food companies (Syngenta, Croda, Mars) and 19 key technology companies (Siemens, 15 SMEs) Together, with innovation spokes eg Catapult (CPI) we aim to provide the UK with the most advanced, integrated capabilities to deliver continuous manufacture, leading to better materials, better value, more sustainable and flexible processes and better health and well-being for the people of the UK and worldwide. CMAC will create future competitive advantage for the UK in medicines manufacturing and chemicals sector and is strongly supported by industry / government bodies, positioning the UK as the investment location choice for future investments in research and manufacturing.

Planned Impact

The CMAC Future Manufacturing Hub team actively engage and collaborate with a wide range of research beneficiaries: leading pharmaceutical companies (e.g. AZ, GSK, Bayer, Pfizer, Lilly); companies in the process industries (e.g. Mars, AB Sugar, Syngenta, Croda); technology and supply chain companies (e.g. Siemens and 15 SMEs). It has a vibrant innovation landscape with partners including; HVM Catapult (CPI); the National Formulation Centre; medical charities (e.g. CRUK), Medicines Manufacturing Industry Partnership (MMIP) of the UK pharma manufacturing industry; Chemical Growth Partnership; International academic partners (Rutgers, Graz, Singapore) through the newly formed International Institute of Advanced Pharmaceutical Manufacturing. This strong, active and influential network of collaborators, stakeholders and business leaders (contributing £31.2m to translate the research into impact), maximises the potential to achieve the Hub vision will create substantial associated impact and benefits including:
1. Economic Impact: contributing to the UK economy by increasing the competitiveness of companies across the £50Bn Pharmaceutical and Chemicals sector. The Hub programme will impact on business innovative capacity and revenues by giving industry access to a 'particle production toolbox' which will increase competitiveness by enabling flexibility of product supply delivered through integrated multi-step continuous manufacturing processes. The Hub will accelerate development and scale up of products with improved costs, energy and material usage, delivering regeneration and economic development opportunities through creation and growth of new companies and jobs through the exploitation and commercialisation of novel processing and platform formulation technologies (potential licensing, spin-out formation) attracting direct inward R&D investment investments from global businesses.
2. Wider Societal Impacts: delivering improvements to life quality and health & wellbeing through improvements to the speed and agility of drug development, manufacture and supply required to meet current unmet customer and patient needs and future demand; availability of a wider range of effective, safe and economically viable products will impact on health across the population. Through smaller plant footprint and reduced energy consumption, continuous manufacturing will deliver lower production costs and significant positive environmental impacts. Engaging with policy-makers and influencing future regulatory frameworks will be a key activity to realise the full potential of these transformative innovations in highly regulated sectors. The manufacturing technology developments will also impact internationally - small modular reconfigurable manufacturing capability with automated, intelligent control has the potential to enable distributed manufacture with units positioned close to the point of need, tackling global priority problems; opportunities for anti-malarial or anti-retroviral products at low cost in developing economies for local distribution to patients will improve access to safe and effective healthcare.
3. Academic Impacts: an interdisciplinary approach to developing new and innovative methodologies and technologies will deliver worldwide academic opportunities in addressing the challenges facing global pharmaceutical and chemicals industries. A unique focus on manufacturing technology and connectivity across multiple stakeholders will enhance the profile of manufacturing research in key sectors of the UK economy, increasing research activity and capacity. Through training highly skilled researchers and attracting talent, a pipeline of knowledge and skilled people will be created for businesses, international collaboration, engagement and research impact (e.g. through co-authored research papers) and new opportunities for UK researchers to obtain international experience via researcher exchanges through CMACs global network.

Organisations

Publications

10 25 50
publication icon
Osorio J (2016) Scaling of continuous twin screw wet granulation in AIChE Journal

publication icon
Warzecha M (2017) Mesoscopic Solute-Rich Clusters in Olanzapine Solutions in Crystal Growth & Design

publication icon
Price C (2017) Engineering Crystallography: From Molecule to Crystal to Functional Form

publication icon
Forbes C (2017) Elucidating the mechanism of paracetamol sonocrystallization for product purity enhancement

publication icon
Lau KH (2017) Self-assembly of ultra-small micelles from amphiphilic lipopeptoids. in Chemical communications (Cambridge, England)

publication icon
Srai JS (2017) Take your medicine - How new research into pharmaceutical supply chains will help you take care of yourself

publication icon
Warzecha M (2017) Direct Observation of Templated Two-Step Nucleation Mechanism during Olanzapine Hydrate Formation in Crystal Growth & Design

publication icon
Nasr MM (2017) Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving From Theory to Practice: September 26-27, 2016, International Symposium on the Continuous Manufacturing of Pharmaceuticals. in Journal of pharmaceutical sciences

publication icon
Settanni E (2017) Pharmaceutical supply chain models: A synthesis from a systems view of operations research in Operations Research Perspectives

publication icon
Srai J (2017) Mapping industrial systems - a supply network perspective on enabling technologies, processes and actors in International Journal of Manufacturing Technology and Management

 
Title Eureka and Discovery: Dr Wei Li, Loughborough University - Lovastatin crystals 
Description Lovastatin is widely used for the treatment of hypercholesterolemia, but the crystalline form of elongated needles is notorious for its poor manufacturability of the final drug product. The aspect ratio of these needle-shaped crystals can be modified by a polymer additive, polypropylene glycol (PPG), which acts as growth blocking agent on selected crystal faces. The fastest growth path along the [100] direction is suppressed while the [010] direction indicating distinctively growth gives spindle body shape. The images show that growth from solution is disrupted on some surfaces resulting in an uneven microstructure, whilst growth on other planes remain relatively flat. Further shape modifications may be obtained using temperature cycles of crystal growth and dissolution, which overall inhibit growth along the a-axis, [100], but with minimal agglomeration and production of fines, leading to a better product for downstream formulation. 
Type Of Art Image 
Year Produced 2018 
Impact The image was 2nd placed in the Eureka and Discovery category of the EPSRC Photo competition 2018. 
URL https://epsrc.ukri.org/newsevents/news/photocompetition2018winner/
 
Title Medicines manufacturing toolbox 
Description Digital image representing medicines manufacturing toolbox 
Type Of Art Image 
Year Produced 2021 
Impact This is part of the University of Strathclyde Images of Research exhibition which is promoted widely to general public across Scotland and especially in Glasgow. 
URL https://www.imagesofresearch.strath.ac.uk/2019/gallery.php
 
Title Twisted Habit of Pharmaceutical Crystals 
Description This image shows twisted crystals of polymorphic form III of oxcarbazepine, a commercially available pharmaceutical drug used to treat epileptic seizures. Pharmaceutical polymorphism is the ability of drugs to exist in multiple crystalline forms that often exhibit different physical and chemical properties. Our research at Strathclyde aims to develop new approaches for controlling polymorphism, thus ensuring that medicines are always administered in the most suitable form for treating patients. 
Type Of Art Image 
Year Produced 2019 
Impact This image was a category winner in the University of Strathclyde "Images of Research" competition. It was exhibited along with other category winners at a number of public venues including along the Clyde outside the Glasgow Science Centre for 1 year. The image also won 1st prize in the Crystals in Art competition at 2019 BACG 
 
Description Phase I Jan 2017- Q1 2021.
Integrated Paracetamol Process. The CMAC Future Manufacturing Research Hub launched its research program with the development of an end-to-end process for the synthesis, purification, isolation and formulation of Paracetamol, an analgesic medicine. In Parallel a prototype digital twin was developed using PSE's gFormulate software. This short project ran from January to June 2017 and built upon the outputs of the CMAC Centre for Innovative Manufacturing (CIM). This short project assessed the current capabilities in development workflows, equipment and modelling to inform future research and it also acted as a platform for developing the new research partnership.
Prototype Lovastatin Microfactory and Digital Twin. Over the period July 2017-October 2019, CMAC developed and tested a novel prototype integrated continuous crystallisation, spherical agglomeration, filter, wash and dry process for the manufacture of Lovastatin. This is a drug where the active ingredient forms difficult to process, needle-like crystals that make the traditional manufacture process difficult and expensive. The new process can be implemented in a laboratory setting using our Microfactory platform with the benefits of a very small space footprint. For the first time, the material from this process was successfully made into tablets using direct compression to produce an oral solid dose form with improved manufacturability. A digital twin of the new Lovastatin process has been developed. It coupled predictive models for solvent screening and selection, crystal growth, and spherical agglomeration to enable simulation of possible conditions of these integrated processes. A set of visualisation tools were developed to support the digital twin. The prototype versions of these were also demonstrated alongside the Lovastatin Microfactory at the CMAC Open Day 2018. Research outputs from this work and the underpinning research supporting it have been added to the common outcomes as they have been disseminated (includes: Hatcher et al, Hatcher, Li et al, McGinty, Chong et al). Additional outputs include a Workflow for Spherical Agglomeration, and Population Balance Model of Spherical Agglomeration models implemented in PSE software, and validated. As part of our advanced characterisation work XPS studies of Lovastatin crystallisation, SEM of continuous antisolvent crystallisation, XPCI of Lovastatin were done to understand nucleation and growth mechanism.
The Mefenamic Acid (MFA) Digital Design and MicroFactory campaign started in December 2018 and ran until summer 2022. The early stages of the campaign looked at whether or not we could integrate the final stage of synthesis with purification and particle engineering downstream. We found we did not have the equipment capability to handle the fully integrated process, so the scope was modified to focus on particle engineering aspects of the process which was tackled using a digital first approach. The campaign built on the previous Hub research to extend that capability by establishing a novel integrated API MicroFactory consisting of seeding vessel, crystalliser and isolation unit and an innovative Drug Product MicroFactory made up of feeder, hot melt extruder and 3D printer. The API production campaign initiated the development of a new overarching, digitally enabled workflow methodology termed Quality by Digital Design that implements predictive models alongside minimal and rapid, small-scale experiments to extract key parameters and information to digitally design the process, understand uncertainty and global sensitivities to inform the MicroFactory test bed control strategy and operation. Extensive flowsheet modelling of end-to-end and individual unit operations provide simulations of process and operating conditions to inform how to run the continuous physical process. Primary processing test bed configuration and data structure has been set up to align with the QbDD Approach and allow for future machine learning work. The work on MFA showed how control of particle size in API material process can be achieved via the Digital First approach. The resulting powder was performance tested in vitro to verify a digital twin of the performance testing of the powder. That allowed us to develop a simple end to end digital twin that was demonstrated in the form of an Android app, at our CMAC Open Days event 16-18th May 2022. Additionally a paper about the MFA API MicroFactory will be submitted in 2023. The MFA campaign progressed development of key modelling elements that had previously been gaps and addressed the operational challenges of integration across the team between modellers and experimentalists and between drug substance and drug product experts. Deviation and delays to original plan for MFA occurred due to Covid and social distancing requirements, and some refinements to the scope of the project so it matched our equipment capability. The lack of face-to-face interaction between the different groups at remote locations over such an extended period made communication and collaboration more difficult than normal, in particular for new starts during 2020-2021. Adapting to emerging challenges presented by the MicroFactory system during the campaign including the equipment and the integrated modelling framework and systems approach will be covered in the MFA MicroFactory and subsequent phase II papers.
Secondary processing (paper by Prasad et al) -showed that Rheology guided process development was successful, but also highlights the limitations of this technique. The targeted immediate release profile for the CSD of MA in Soluplus®-Sorbitol formulation has been met, whilst the stable crystalline form (I) of MFA has been retained and the consistency of drug release has been significantly improved. A novel MicroFactory prototype, combining Feeder, Hot Melt Extruder and 3D printer, has successfully produced MA tablets and a patent application has been submitted The A recent work from the Hub (Prasad, E.; Robertson, J.; Halbert, G. W. 2022) shows that formulation of MFA OSDs can be modified such that the immediate release profile is more consistent and exceeds that of commercially available tablets via use of a prototype combined Hot melt extruder and 3D printer MicroFactory platform (PG449245GB) that has been developed in CMAC on an aligned project.
In 2021 the Hub had a successful Mid-term Review and then kicked off phase II of the Hub research as described in the 2020 CMAC Hub Annual Review and revised in the 2021 CMAC Hub Annual Review. https://cmac.ac.uk/cmac-annual-reviews
During phase II new strands of activity have been established. First, a novel crystallisation classification system DataFactory has been initiated and is currently being established. It includes elements to address experimental requirements in the early stage of the QbDD workflow and is supported with new RPIF funded robotics and associated hardware. Ongoing tasks included automation and integration of the robots, and development of smart experiments using AI. In 2023 the capability of the crystallisation DataFactory will be expanded further to include additional advanced measurement capability and to increase the number of experiments that can be ran in parallel.
The second activity is the WP2.3 Drug product performance modelling work that's kicked off at Sheffield and aligns with PhD and the Pressure-dependent In-Situ Monitoring of Granular Materials (EP/S02168X/1) project. The development of these models is planned such that they can become an integrated part of the WP2.1 QbDD Workflow.
Exploitation Route The pre-competitive CMAC Future Manufacturing Research Hub programme has been co-created with our industry partners (at March 2023 these are AstraZeneca, Chiesi, Lilly, Novartis, Pfizer, Roche, Takeda, UCB with Sanofi about to join). The research outputs have been demonstrated at CMAC Open Days in 2018, 2020, 2022 via live demonstrations, talks, and posters. Research outputs are being disseminated via publications, talks, posters and internal reports. Learnings form this project are expected to be translated to industry partners through routes including researcher placements, CPD training, translation focused seminars, digital apps, and knowledge applied to proprietary industry projects run by CMAC in parallel with the Hub programme. The academic team working on the pre-competitive CMAC Future Manufacturing Research Hub programme will take the learnings from Phase I and II and apply them across CMAC. This work also linked to the research done on the aligned and now completed EPSRC ARTICULAR project (EP/R032858/1).
In 2022 two new posts, funded by UKRI rapid calls, started in Q2. The Hub Impact Officer and Digital Developer have started to implement pathways to impact plans with a focus on translating digital assets and workflows both internally and across the portfolio of projects and to our Tier 1 partners. The Spherical Agglomeration workflow dissemination to partners is well progressed and the Cooling Crystallisation workflow have been disseminated to our Industry partners. A CPD course on Cooling Crystallisation is being developed and rolled out with Part one having over 20 people in CMAC and the Industry Tier1 partners "beta test" it during 2022. An AssetStore to capture CMAC Digital Assets as they are developed has been launched in 2022 with plans to utilize more extensively in 2023. A plan for further dissemination and translation of the research outputs from Hub to the Tier1 partners is in place.
The Quality by Digital Design Workflows that were initiated during the MFA campaign have been further developed and are currently being used to deliver three more API manufacture campaigns during 2023. The outputs of this work will include a paper outlining what QbDD is and the context within the Medicines Manufacturing landscape, what QbDD work CMAC has done, and the importance and potential impact of this approach. The data from the three QbDD driven API Microfactories currently underway will be used for a second paper that will exemplify practically implementing the approach. We have an Open Days event taking place on 14-16 Nov 2023 where we will showcase the QbDD Workflows and the research and translation work done during Phase II of the Hub. We are currently working with our Industry Partners to ensure we are fully aligned in terms of what the QbDD Workflows develop in CMAC can deliver for Industry.
Sectors Chemicals,Digital/Communication/Information Technologies (including Software),Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology
 
Description Areas where we have delivered demonstrable impact are: 1) Prove, demonstrate (and in some case deliver platform capabilities and equipment) new ideas and concepts that companies do not have enough time or expertise to try themselves. Predictive design exploiting model-driven workflows plus end-to-end digital twin development and concepts, MicroFactory development and operation, and advanced future supply chain concepts focused around distributed manufacturing of medicines. Progress in the award is reinforcing the opportunities to support future medicines supply chains. Flexible MicroFactories now appear within the UK Medicines Manufacturing Industry Partnership (MMIP) technology and innovation roadmap. 2) Develop new workflows to efficiently and effectively develop processes and gain process understanding saving time, reducing risk and reducing resources required. We have developed the Quality by Digital Design (QbDD) Workflows Approach where we do a digital first approach to Quality by Design (QbD) to deliver Microfactory Processes. There are many tools and workflows included in this. These include solubility prediction tools, advanced workflows for crystallisation development including impurity rejection, drug product manufacturability via Hot Melt Extruder/ 3DPrint workflow. 3) New measurement techniques including the use of ToF-SIMS, EXAFS, PDF, THz has been developed and applied to a range of rate processes and materials to provide new insights to structure-process-performance relationships. 4) Address real-time live manufacturing development challenges on commercial products delivering impacts including reduced waste, improved quality, improved reproducibility, lower costs, reduced plant down-time. During 2021 CMAC reached its 10-year anniversary as a result of the EPSRC Centre for Innovative Manufacturing for Continuous Manufacturing and Crystallisation (EP/I033459/1) and Future Continuous Manufacturing and Advanced Crystallisation Research Hub funding. At the celebration online event in November 2022, a forward strategy for the portfolio of projects, including and underpinned by the Hub, was published CMAC_Strategy_21-26+(6).pdf (squarespace.com). This strategy launch was aligned with a refresh of Tier 1 membership. Current members are: AstraZeneca, Chiesi, Lilly, Pfizer, Roche, Takeda, UCB. New members are Chiesi and UCB. The Hub has a role to act as a National Centre and as such has aligned with key Policy. This includes alignment with MMIP mission to support the UK to become a leading force in manufacturing innovation, ABPI's Manufacturing vison for the UK, The Made Smarter Report, FDA vision for Global Pharma. CMAC strategy includes aiming to achieve greater speed, quality, agility, security and sustainability, in pharmaceutical manufacturing and communicating and engaging around the need for advanced pharmaceutical manufacturing, analytics and industrial digital technology development. The need for skilled people to address the gap in Digital Transformation and Data-Driven Research has been highlighted. The UK has supported the portfolio of aligned projects underpinned by the Hub investment. The CMAC Skills pillar starts to address the requirements of the talent pipeline, and our industry partners have noted how the doctoral training at CMAC produces uniquely skilled people. Significant further funding has been awarded because of the Hub award. This has been updated in the common outcomes section and includes the awards. In 2022 CMAC hosted an in person 3-day event that combined the ARTICULAR (EP/R032858/1) Showcase, DM2 (EP/V062077/1) launch and CMAC Open Days. Day 2 will focused directly on Hub research outputs and Day 3 on translation to Industry and formal launch of the aligned DM2 research programme Day 1 is focused on ARTICULAR research outputs. The next CMAC Open Days event will be taking place on 14-16th Nov 2023. In 2021 the Hub refreshed its ED&I policy and training and implemented a CMAC ED&I Committee with the objective to continually improve diversity and inclusion in the workplace. The Hub Phase II plan, including implementation and development of QbDD and the CCS DataFactory has commenced in early 2021 and will continue to end of 2023. A plan for dissemination and translation of the research outputs to the Tier1 partners is in place and supported by the Hub From October 2022 to March 2023 CMAC received a supplement of additional funds which are being used to accelerate research delivery and paper writing, and to support an early career researcher training event. This activity is on track to be completed successfully.
First Year Of Impact 2018
Sector Chemicals,Digital/Communication/Information Technologies (including Software),Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology
Impact Types Societal,Economic
 
Description ARTICULAR: ARtificial inTelligence for Integrated ICT-enabled pharmaceUticaL mAnufactuRing
Amount £1,965,119 (GBP)
Funding ID EP/R032858/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 07/2018 
End 06/2022
 
Description Accelerated Discovery and Development of New Medicines: Prosperity Partnership for a Healthier Nation
Amount £5,495,023 (GBP)
Funding ID EP/S035990/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 01/2019 
End 12/2023
 
Description Advanced Manufacturing Challenge Fund: SCOUT
Amount £1,084,500 (GBP)
Organisation Government of Scotland 
Sector Public
Country United Kingdom
Start 04/2020 
End 12/2022
 
Description Application of process analytical technology (PAT) for monitoring and controlling of reactive crystallisation systems
Amount £62,079 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 10/2021 
End 09/2024
 
Description CMMI-EPSRC - Right First Time Manufacture of Pharmaceuticals (RiFTMaP)
Amount £1,543,632 (GBP)
Funding ID EP/V034723/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 08/2021 
End 08/2024
 
Description Computer aided solvent design to minimise solvent use in integrated synthesis, purification & isolation for sustainable pharmaceutical manufacturing
Amount £1,351,896 (GBP)
Funding ID EP/W01923X/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 07/2022 
End 07/2025
 
Description Deep Generative Models for Pharmaceutical Manufacturing Process Design
Amount £52,573 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 01/2021 
End 12/2023
 
Description Development of the next generation instrumented dissolution apparatus
Amount £82,300 (GBP)
Funding ID 2441956 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2020 
End 09/2024
 
Description Dialling up performance for on demand manufacturing
Amount £5,865,535 (GBP)
Funding ID EP/W017032/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2022 
End 09/2027
 
Description Digital Design Accelerator Platform to Connect Active Material Design to Product Performance
Amount £1,793,361 (GBP)
Funding ID 105811 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2020 
End 02/2022
 
Description Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP)
Amount £1,251,700 (GBP)
Funding ID EP/W003295/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2021 
End 03/2025
 
Description Digital design strategies for industrial crystallisation development: Considering active pharmaceutical ingredient properties and crystalliser hydrodynamics for process scale up
Amount £51,293 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 06/2020 
End 05/2024
 
Description Discovery and Applications of Novel Solid-State Structures: Water Bridges Salt Forms
Amount £73,018 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 01/2022 
End 03/2025
 
Description Enhancing virtual tablet formulation design
Amount £83,956 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 12/2021 
End 09/2025
 
Description Establishing a UK Medicines Manufacturing Innovation Centre
Amount £13,000,000 (GBP)
Funding ID 104208 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 05/2018 
End 12/2021
 
Description Flow-Xl: A New UK Facility for Analysis of Crystallisation in Flow Systems
Amount £1,129,049 (GBP)
Funding ID EP/T006331/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 04/2020 
End 03/2022
 
Description In situ measurements of interfacial concentration enhancement in solutions
Amount £60,957 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 10/2020 
End 09/2023
 
Description In-situ Monitoring of Flowing Pharmaceutical Powders
Amount £95,293 (GBP)
Funding ID 2267922 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2019 
End 09/2023
 
Description Insights into surface structural dynamics for particle property control
Amount £117,000 (GBP)
Funding ID 2595140 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2021 
End 09/2025
 
Description KTP 11937 UoStrathclyde / PSE
Amount £136,917 (GBP)
Funding ID KTP 11937 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 08/2019 
End 09/2022
 
Description Linking digital manufacturing to a digital tablet: Simulating tablet disintegration using discrete element and pore-scale modelling
Amount £76,000 (GBP)
Organisation Government of Scotland 
Department Scottish Funding Council
Sector Public
Country United Kingdom
Start 11/2018 
End 10/2022
 
Description Liquid additive layer manufacturing for pharmaceutical products
Amount £58,374 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2019 
End 09/2022
 
Description Made Smarter Innovation - Digital Medicines Manufacturing Research Centre
Amount £5,086,406 (GBP)
Funding ID EP/V062077/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2021 
End 03/2025
 
Description Medicines Manufacturing Innovation Centre
Amount £160,000 (GBP)
Funding ID 900070 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 05/2017 
End 03/2018
 
Description Modelling agglomeration and breakage during agitated vacuum thermal drying
Amount £85,900 (GBP)
Funding ID 2267867 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2019 
End 09/2023
 
Description Modelling and AI-Driven Optimisation of Pharmaceutical Tablet Manufacturing
Amount £62,079 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 02/2022 
End 01/2025
 
Description Multi-User Facility for SAXS/WAXS Studies on Nanoscale Structures in Controlled Environments.
Amount £1,183,496 (GBP)
Funding ID EP/R042683/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 06/2018 
End 05/2023
 
Description Novel approaches for solubility prediction based on molecular modelling and machine learning
Amount £62,079 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 10/2021 
End 09/2024
 
Description Predicting Performance of Medicines: Disintegration and Dissolution of Pharmaceutical Tablets
Amount £82,300 (GBP)
Funding ID 2570328 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 06/2021 
End 12/2024
 
Description Rapid Calls: EPSRC Rapid Call funding for 2 new posts (Impact Officer & Coding Technician)
Amount £149,919 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 05/2021 
End 12/2023
 
Description Rapid, green and self-optimised additive manufacturing of medicines
Amount £73,018 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 10/2021 
End 03/2025
 
Description Real time X-ray imaging of crystallisation processes
Amount £73,018 (GBP)
Organisation University of Leeds 
Sector Academic/University
Country United Kingdom
Start 10/2021 
End 09/2025
 
Description Reducing Greenhouse Gas Emissions through Understanding the Molecular Basis of Friction and Its Control: Towards a Step Change through Use of Novel In Situ X-ray Analysis Techniques
Amount £134,000 (GBP)
Funding ID EP/R511717/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 04/2020 
End 03/2021
 
Description Understanding Long-Term Stability of Solid Pharmaceutical Dosage Forms by Characterisation of the Composite Materials at Short (Nano) Scale Length Scales to Enable Modelling and Prediction of Emergent Time-Dependent Physico-Chemical Changes
Amount £303,000 (GBP)
Funding ID CAMS2021/IPostD/03 
Organisation Community of analytical measurement sciences 
Sector Private
Country United Kingdom
Start 07/2021 
End 06/2023
 
Description Understanding the mechanisms and mitigating the undesirable effects of drying on active pharmaceutical ingredient particle properties
Amount £59,850 (GBP)
Organisation University of Strathclyde 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 09/2021
 
Description University of Sheffield and Process Systems Enterprise Limited
Amount £144,336 (GBP)
Funding ID 511630 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 04/2019 
End 04/2021
 
Description Using Artificial Intelligence to predict crystal structures
Amount £38,666 (GBP)
Organisation Cambridge Crystallographic Data Centre 
Sector Academic/University
Country United Kingdom
Start 01/2018 
End 12/2021
 
Title Recirculating Liquid Jet Cell for In Situ X-ray Absorption Spectroscopy 
Description A liquid jet setup for general windowless X-ray absorption spectroscopy at beamline B18 of Diamond Light Source, UK 
Type Of Material Improvements to research infrastructure 
Year Produced 2019 
Provided To Others? Yes  
Impact Enhanced use of the Diamond B18 facility for moelcular level sructure studies of liquid flowing systems 
 
Title Computer-aided solvent mixture design for the crystallisation and isolation of mefenamic acid 
Description The files contain the MINLP formulations presented in this publication. The MINLP problems are implemented and solved in GAMS version 28.2.0, using SBB, a local branch-&-bound MINLP solver. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
Impact Application to pharmaceutical process development 
URL https://zenodo.org/record/3628747
 
Title Data for: "A micro-XRT Image Analysis and Machine Learning Methodology for the Characterisation of Multi-Particulate Capsule Formulations" 
Description This is a collection of data and methodologies used in the following publication. Public access to the dataset is currently under embargo until 01/01/2022, as data forms part of ongoing research. Expressions of interest can be made via the contact email: researchdataproject@strath.ac.uk. Further details on the data can be found in the README file provided. Title: A micro-XRT Image Analysis and Machine Learning Methodology for the Characterisation of Multi-Particulate Capsule Formulations Authors: Frederik J. S. Doerr and Alastair J. Florence Journal: International Journal of Pharmaceutics Accepted Date: 18/11/2019 DOI: https://doi.org/10.1016/j.ijpx.2020.100041 Abstract: The application of X-ray microtomography for quantitative structural analysis of pharmaceutical multi-particulate systems was demonstrated for commercial capsules, each containing approximately 300 formulated ibuprofen pellets. The implementation of a marker-supported watershed transformation enabled the reliable segmentation of the pellet population for the 3D analysis of individual pellets. Isolated translation- and rotation-invariant object cross-sections expanded the applicability to additional 2D image analysis techniques. The full structural characterisation gave access to over 200 features quantifying aspects of the pellets' size, shape, porosity, surface and orientation. The extracted features were assessed using a ReliefF feature selection method and a supervised Support Vector Machine learning algorithm to build a model for the detection of broken pellets within each capsule. Data of three features from distinct structure-related categories were used to build classification models with an accuracy of more than 99.55% and a minimum precision of 86.20% validated with a test dataset of 886 pellets. This approach to extract quantitative information on particle quality attributes combined with advanced data analysis strategies has clear potential to directly inform manufacturing processes, accelerating development and optimisation. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
URL https://pureportal.strath.ac.uk/en/datasets/e5d22969-77d4-46a8-83b8-818b50d8ff45
 
Title Data for: "Conundrum of gamma glycine nucleation revisited: to stir or not to stir" 
Description Raw data for the paper is available as a zip file. The raw characterisation data for polymorphic identification for crystals is available as: • Fourier-transform infrared spectroscopy (FT-IR): raw spectra data as text file (.txt) and experimental results summarized in a pdf file (.pdf). • X-Ray Powder Diffraction (XRPD): raw spectra data as text file (.raw) and processed spectra data as text file (.xy). and crystal morphology data is available as: • Optical microscopic images: image files (.jpg). • Pictures of the vials: image files (.jpg) The data corresponds to the different setups and cooling temperatures presented in Figure 5 of the paper (see Figure 5.pdf). The figure has 8 parts, each with 6 concentrations. The directory structure is as follows: • Figure 5X-Setup [1/2][a/b] o YYYgGlycine-kgWater ? Morphology • Vial (AAA).jpg • Optical microscopy-sample AAA-X.JPG ? Polymorphic identification • FTIR o Sample AAA.txt o Summary.pdf • XRPD o AAA.raw o AAA.xy for example: Figure 5g-Setup 2a > 450gGlycine-kgWater > Polymorphic identification > FTIR > Sample 66G.txt The data from quenched experiments presented in SI Figure 2 in the Supplementary Information (see SI Figure 2.pdf) is also available under: SI Figure 2-Setup 1c > YYYgGlycine-kgWater > Polymorphic identification > FTIR > Sample AAA.txt 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? Yes  
 
Title Data for: "Data mining crystallization kinetics" 
Description This is the dataset associated with the article titled "Data mining crystallisation kinetics". Files within this dataset: Molecular descriptors employed in random forests of the compounds in the database (moe_descriptors.csv) All the data collected without pre-processing, observations whose kinetic parameters were a function of solvent or antisolvent concentration, observations whose growth was measured as volume, data adjusted according to what was explained in the article (dataset_raw.csv) All the data collected with preprocessing, observations whose kinetic parameters were a function of solvent or antisolvent concentration, observations whose growth was measured as volume, data adjusted according to what was explained in the article (dataset_preprocessed.csv) Code employed to perform cluster analysis and random forests in R (script.html) 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
URL https://pureportal.strath.ac.uk/en/datasets/8f47a175-3ac7-4791-a310-82e6652bd9f5
 
Title Data for: "Degradation behavior of silk nanoparticles - enzyme responsiveness" 
Description Native and PEGylated silk nanoparticles have been developed and designed for lysosomotropic drug delivery that they ultimately traffic into lysosomes, where the low pH and lysosomal enzymes trigger payload release. Our aim was therefore to investigate degradation behaviour of native and PEGylated silk nanoparticles in protease enzymes (protease XIV and a-chymotrypsin), a cysteine protease (papain) and ex-vivo enzymes from lysosomes. All datasets for each figure provided in separate zipped folders. All measurements, equipment and software used in this study are detailed in the Readme file provided. 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
 
Title Data for: "Developing a batch isolation procedure and running it in an automated semi-continuous unit" 
Description Dataset related to paper Developing a batch isolation procedure and running it in an automated semi-continuous unit: AWL CFD25 case study (https://doi.org/10.1021/acs.oprd.9b00512). This data set contains two folders: AWL DOE Dec 2017 and conti run PCM 220119. In the first folder all the raw and analysed data related to the isolation process development in batch mode (DOE) are reported (related to section 3.1 of the paper). In conti run PCM 220119 instead all the raw and analysed data of the continuous run are reported (relative to section 3.2 of the paper). 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
URL https://pureportal.strath.ac.uk/en/datasets/de7fb226-49f2-4e08-83da-68ff27acbe3f
 
Title Data for: "Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing" 
Description Dataset related to paper Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing (https://doi.org/10.1016/j.xphs.2018.07.005) and for the proceeding of the Filtech 2016 conference. This dataset comprises of one zip file which contains a number of folders containing spreadsheets, images text supporting experiments. 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
URL https://pureportal.strath.ac.uk/en/datasets/ac8c0e36-72d3-4156-9fbe-e60293e33a72
 
Title Data for: "Improving consistency for a Mefenamic acid immediate release formulation" 
Description This data set supports the findings of the study 'Improving consistency for a Mefenamic acid immediate release formulation' published in the Journal of Pharmaceutical Sciences. Data is provided in Microsoft excel format. Original data files are available upon request. Particle size analysis data - Qic/PIC, dynamic imaging system, equipped with the Rhodos attachment from Sympathec Rheology: Temperature sweep and Frequency sweep data - Haake Mars III rotational rheometer Hot-melt-extrusion process data - Process 11, Thermo Fisher Filament diameter data Mechanical testing: Texture Analyser TA-XT (Stable Micro Systems) equipped with a mini 3-point bend rig HPLC data and method validation - Agilent 1100 LC system equipped with G1315A Diode Array Detector Dissolution test data: ADT8i Dissolution bath (USP I, basket) apparatus with a closed loop setting and a T70+ UV/Visible Spectrophotometer (Automated Lab Systems) 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
URL https://pureportal.strath.ac.uk/en/datasets/18916640-5b9d-4bea-afed-db2e1ca0f207
 
Title Data for: "Manual versus Microfluidic-assisted Nanoparticle Manufacture: Impact of Silk Fibroin Stock on Nanoparticle Characteristics" 
Description These files contain quantitative data sets (Excel sheets) for the respective figures shown in the research paper and SI information. The particle characteristics are qualitatively assessed by scanning electron microscopy (image are JPEG and TIF formats). Technical information for the SEM images are included. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
URL https://pureportal.strath.ac.uk/en/datasets/7387b6dc-f207-4c2f-8f97-94b3bd651468
 
Title Data for: "Peptide Isolation via Spray Drying: Particle Formation, Process Design and Implementation for the Production of Spray Dried Glucagon" 
Description This is a collection of data and methodologies used in the following publication. Public access to the dataset is currently under embargo until 01/01/2021. Expressions of interest can be made via the contact email: researchdataproject@strath.ac.uk. Further details on the data can be found in the README file provided. Title: Peptide Isolation via Spray Drying: Particle Formation, Process Design and Implementation for the Production of Spray Dried Glucagon Authors: Frederik J. S. Doerr, Lee J. Burns, Becky Lee, Jeremy Hinds, Rebecca L. Davis-Harrison, Scott A. Frank, Alastair J. Florence Journal: Pharmaceutical Research Accepted Date: 28/09/2020 DOI: (tbc) Abstract: Purpose Spray drying plays an important role in the pharmaceutical industry for product development of sensitive bio-pharmaceutical formulations. Process design, implementation and optimisation require in-depth knowledge of process-product interactions. Here, an integrated approach for the rapid, early-stage spray drying process development of trehalose and glucagon on lab-scale is presented. Methods Single droplet drying experiments were used to investigate the particle formation process. Process implementation was supported using in-line process analytical technology within a data acquisition framework recording temperature, humidity, pressure and feed rate. During process implementation, off-line product characterisation provided additional information on key product properties related to residual moisture, solid state structure, particle size/morphology and peptide fibrillation/degradation. Results A psychrometric process model allowed the identification of feasible operating conditions for spray drying trehalose, achieving high yields of up to 84.67%, and significantly reduced levels of residual moisture and particle agglomeration compared to product obtained during non-optimal drying. The process was further translated to produce powders of glucagon and glucagon-trehalose formulations with yields of >83.24%. Extensive peptide aggregation or degradation was not observed. Conclusions The presented data-driven process development concept can be applied to address future isolation problems on lab-scale and facilitate a systematic implementation of spray drying for the manufacturing of sensitive bio-pharmaceutical formulations. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
URL https://pureportal.strath.ac.uk/en/datasets/dcb859db-fe0d-4a56-b001-3f3d7ac6c44a
 
Title Data for: "Quantitative Investigation of Particle Formation of a Model Pharmaceutical Formulation using Single Droplet Evaporation Experiments and X-Ray Tomography" 
Description This is a collection of data and methodologies used in the following publication. Public access to the dataset is currently under embargo, as data forms part of ongoing PhD research. Expressions of interest can be made via the contact email: researchdataproject@strath.ac.uk Title: Quantitative Investigation of Particle Formation of a Model Pharmaceutical Formulation using Single Droplet Evaporation Experiments and X-Ray Tomography Authors: Frederik J. S. Doerr, Iain D. H. Oswald, Alastair J. Florence Accepted Date: 18/09/2018 DOI: 10.1016/j.apt.2018.09.027 Abstract: The implementation of a particle design platform that can be applied to novel pharmaceutical systems using acoustic levitation (SAL) and X-ray tomography (XRT) is discussed. Acoustic levitation was employed to provide a container-less particle design environment for single droplet evaporation experiments. Dried particles were subject to further visual and quantitative structural analysis using X-ray tomography to assess the three-dimensional volume space. The workflow of the combined SAL-XRT platform has been applied to investigate the impact of increasing HPMC K100LV concentrations on the evaporation, drying and final particle morphology of particles from a model pharmaceutical formulation containing metformin and D-mannitol. The morphology and internal structure of the formulated particles after drying are dominated by a crystalline core of D-mannitol partially suppressed with increasing HPMC K100LVadditions. The final structure can be correlated to the observed evaporation kinetics. The characterisation of formulated metformin hydrochloride particles with increasing polymer content demonstrated the importance of an early-stage quantitative assessment of formulation related particle properties. The ability to study the evolution of solid phase formation and its influence on the final particle morphology can enable the selection of formulation and process parameter that deliver the desired particle structure and consequent performance by design. 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
 
Title Data for: "The impact of paracetamol impurities on face properties: investigating the surface of single crystals using TOF-SIMS" 
Description AFM, TOF-SIMS, LC-TOF, optical microscope, raman microscopy, single crystal x-ray, SEM, solubility and UV-vis spectrometery data of paracetamol and 4-nitrophenol single crystals and on face impurities 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
 
Title Data for: "Understanding effect of filtration and washing on dried product: Paracetamol case study" 
Description Dataset related to paper Understanding effect of filtration and washing on dried product: Paracetamol case study (https://doi.org/10.1016/j.powtec.2020.02.064). This data set contains three folders: filtration-washing-drying, sedimentation, wettability folders. In filtration-washing-drying you find the data related to section 4.1 (parameter affecting filtration (excluded the sedimentation part), section 4.2, section 4.3, section 4.4, section 4.5. In sedimentation folder you find data related to the filtration experiments where sedimentation of particles were occurring (pre-settling cake prior filtration or reloading filtrate on top of the cake to re-filtering it again. In folder wettability you find the Washburn experiments described in the supplementary information section. In SAM data_solubility analysis excel document a list of solubility by equilibration data are reported. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
URL https://pureportal.strath.ac.uk/en/datasets/cce27859-8c9f-4925-96de-b32711fae0c3
 
Title Data for:"Microfluidic-assisted silk nanoparticle tuning" 
Description The current manufacture of silk nanoparticles using desolvation method is time-consuming and lack ability to tune nanoparticle characteristics. Over the last decade, microfluidics has been developed which enables to manipulate particle properties by fine-tuning process parameters such as the total flow rate and flow rate ratios. Our aim was therefore to manufacture silk nanoparticles by desolvation using the NanoAssemblrTM microfluidic setup. All datasets for each figure provided in separate zipped folders. All measurements, equipment and software used in this study are detailed in the Readme file provided 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
 
Title Dataset for "Continuous flow for materials synthesis, assembly and crystallisation at Diamond: discovery and delivery of high value materials" 
Description Continuous crystallisation of the model system Carbamazepine (CBZ) in ethanol in the KRAIC-D (Kinetically Regulated Automated Input Crystalliser - Diffraction) platform on beamline I11 (high resolution powder diffraction) is presented. The effect of introducing a controlled solid interface into the crystallisation process is investigated, where CBZ form III seeds are introduced in polymorphic purity at different seeding positions (pre- and post-nucleation) throughout the length of the KRAIC-D. The video associated with Chapter 4 corresponds with a post-nucleation CBZ form III experiment where a separation of crystal habit is observed as a result of the different interaction with the flow paths in the solution slugs with the segmented flow. The second device is the KRAIC-S (Kinetically Regulated Automated Input Crystalliser - Single Crystal) platform installed at I19 (small molecule single crystal beamline) employed to investigate the continuous crystallisation of paracetamol (PCM) in 60:40 water:isopropanol via a range of experiments including unseeded and seeded cooling crystallisations. The unseeded experiments also looked at the crystallisation at different set points along the KRAIC-S (6.7 m and 8.7 m) to investigate crystal growth and crystal rotation at different length scales. The videos associated with Chapter 5 include single crystals produced from the range of experiments investigated. Each video tracks a different single crystal in a solution slug, where through use of the slug triggering mechanism, whereby an optical trigger prompts translation of the motorised stage to artificially suspend the single crystal in the X-ray beam during data collection. These videos complement the diffraction data and can provide explanation for data collections, which do not achieve cell indexation as the single crystal is shown to move in and out of the X-ray beam in these videos. 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
URL https://researchdata.bath.ac.uk/id/eprint/779
 
Title Description of the thermodynamic properties and fluid-phase behaviour of aqueous solutions of linear, branched, and cyclic amines. AIChE J 2021 
Description All computational data for figures presented in the publication. 
Type Of Material Database/Collection of data 
Year Produced 2021 
Provided To Others? Yes  
Impact Use in the modelling of complex mixtures of fluids, including in pharmaceutical process development and in CO2 capture. 
URL https://zenodo.org/record/4488482
 
Title Extending the SAFT- ? Mie approach to model benzoic acid, diphenylamine, and mefenamic acid: Solubility prediction and experimental measurement 
Description All computational and measured data in the publication. 
Type Of Material Database/Collection of data 
Year Produced 2021 
Provided To Others? Yes  
Impact Use in models of complex mixtures in pharmaceutics and separations 
URL https://zenodo.org/record/4700674
 
Title Model-based solvent selection for integrated synthesis, crystallisation and isolation processes 
Description We present a systematic process-wide solvent selection tool based on computer-aided mixture/blend design (CAMbD) (Gani, 2004) for the integrated synthesis, crystallisation and isolation of pharmaceutical compounds. The method proposed simultaneously identifies the solvent and/or antisolvent mixture, mixture composition and process temperatures that optimise one or more key performance indicators. Additionally, the method entails comprehensive design specifications for the integrated process, such as the miscibility of the synthesis, crystallisation and wash solvents. The design approach is illustrated by identifying optimal solvent mixtures for the synthesis, crystallisation and isolation of mefenamic acid. Furthermore, a multi-objective CAMbD problem is formulated and shows that a mefenamic acid with purity of 98.8% can be achieved without significant loss of process performance in terms of the solvent E-factor. 
Type Of Material Database/Collection of data 
Year Produced 2022 
Provided To Others? Yes  
Impact Use in the development of pharmaceutical processes. New funding secured. 
URL https://zenodo.org/record/5585546
 
Description AWL are Tier 2 Members of CMAC - Hub 
Organisation Alconbury Weston Ltd
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution AWL are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year 2017
 
Description Analytik/Laminar 
Organisation Analytik Ltd
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Analytik/Laminar are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year 2021
 
Description Anatune 
Organisation Anatune
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub .
Collaborator Contribution Anatune are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year 2020
 
Description AstraZeneca - Hub Tier 1 Partner 
Organisation AstraZeneca
Department Research and Development AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub .
Collaborator Contribution AstraZeneca are Tier 1 members of CMAC.
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description AstraZeneca - Hub Tier 1 Partner 
Organisation University of Strathclyde
Country United Kingdom 
Sector Academic/University 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub .
Collaborator Contribution AstraZeneca are Tier 1 members of CMAC.
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description Bayer - Hub Tier 1 Partner 
Organisation Bayer
Country Germany 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Bayer were Tier 1 members of CMAC.
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description Blacktrace are Tier 2 Members of CMAC - Hub 
Organisation Blacktrace Holdings Ltd
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Blacktrace are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year 2017
 
Description Britest - are Tier 2 Members of CMAC - Hub 
Organisation Britest
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Britest are Tier 2 members of CMAC. They have provided training and problem solving workshops for the Hub Team.
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year 2017
 
Description Buchi - Tier 2 Members of CMAC - Hub 
Organisation Büchi Labortechnik
Country Switzerland 
Sector Hospitals 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Buchi were Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme. In this case research involving the Buchi spray dryer.
Start Year 2017
 
Description CCDC are Tier 2 Members of CMAC - Hub 
Organisation Cambridge Crystallographic Data Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution CCDC are Tier 2 members of CMAC. They jointly supported a PhD aligned with Hub and assisted with delivery of the Lovastatin project by use of the CCDC reporting tools. The Hub uses the databases as part of the Quality by Digital Design approach.
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year 2019
 
Description Chiesi are Tier 1 Members of CMAC - Hub 
Organisation Chiesi
Country Italy 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Chiesi re Tier 1 members of CMAC
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2021
 
Description Clairet Scientific Ltd are Tier 2 Members of CMAC - Hub 
Organisation Clairet Scientific
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Clairet Scientific Ltd are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year 2017
 
Description EDEM / Alatair - are Tier 2 Members of CMAC - Hub 
Organisation Altair Engineering Ltd
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution EDEM / Alatair are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year 2017
 
Description GSK - are Tier 1 Members of CMAC - Hub 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution AstraZeneca are Tier 1 members of CMAC
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description Lilly are Tier 1 Members of CMAC - Hub 
Organisation Eli Lilly & Company Ltd
Department Neuroscience Eli Lilly
Country United States 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Lilly are Tier 1 members of CMAC
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description M-Star are Tier 2 Members of CMAC - Hub 
Organisation M-Star Simulations LLC
Country United States 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution M-Star are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year 2021
 
Description Nitech 
Organisation NiTech Solutions Ltd
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Nitech are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year 2017
 
Description Novartis are Tier 1 Members of CMAC - Hub 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Novartis are Tier 1 members of CMAC
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description PWC -Tier 2 Members of CMAC - Hub 
Organisation Price Waterhouse Cooper
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution PWC are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year 2017
 
Description Perceptive Enginnering Ltd / Applied Materials are Tier 2 Members of CMAC - Hub 
Organisation Perceptive Engineering Ltd
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Perceptive Enginnering Ltd / Applied Materials are Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme. In this case it was implementing PharmaMV on process equipment.
Start Year 2017
 
Description Pfizer are Tier 1 Members of CMAC - Hub 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Pfizer are Tier 1 members of CMAC
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description Roche are Tier 1 Members of CMAC - Hub 
Organisation Roche Pharmaceuticals
Country Global 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Roche are Tier 1 members of CMAC
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description Siemens (PSE) are Tier 2 Members of CMAC - Hub 
Organisation Siemens AG
Department Siemens plc
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Siemens (PSE) are Tier 2 members of CMAC. The work specifically is on gFormulated Products and gPROMS.
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year 2017
 
Description Sirius Analytical are Tier 2 Members of CMAC - Hub 
Organisation Syrius Analytical Instruments Ltd
Country United Kingdom 
Sector Private 
PI Contribution University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Sirius Analytical were Tier 2 members of CMAC
Impact CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year 2017
 
Description Takeda - are Tier 1 Members of CMAC - Hub 
Organisation Takeda Pharmaceutical Company
Department Takeda Pharmaceuticals U.S.A., Inc. (TPUSA)
Country United States 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution Takeda are Tier 1 members of CMAC
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2017
 
Description UCB - are Tier 1 Members of CMAC - Hub 
Organisation UCB SA
Country Belgium 
Sector Private 
PI Contribution University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution UCB are Tier 1 members of CMAC
Impact CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year 2022
 
Description 03 April 2017 edition of Chemistry World. "The flow revolution" 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Article in Chemistry World Magazine that includes CMAC
Year(s) Of Engagement Activity 2017
URL https://www.chemistryworld.com/feature/the-flow-revolution/2500496.article
 
Description 16 November , The Scotsman, "Fast-track medicine base in Scotland could be a game changer" . 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Article about CMAC in Scotsman newspaper / online
Year(s) Of Engagement Activity 2017
URL https://www.scotsman.com/business/fast-track-medicine-base-in-scotland-could-be-a-game-changer-1-461...
 
Description 18 December 2017 - CMAC Welcomes Pfizer as Newest Partner 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Press release to announce that Pfizer joined CMAC as tier 1 Industry Partners
Year(s) Of Engagement Activity 2018
URL http://www.strath.ac.uk/whystrathclyde/news/cmacwelcomespfizerasnewestpartner/
 
Description 2021 Kuopio: Prodrug technology and Continuous processing workshops & Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Kuopio: Prodrug technology and Continuous processing workshops & Meeting with FinPharmaNet for graduate students (online, 27-28th Aug 2021) https://nordicpop.ku.dk/events/kuopio-meeting-together-with-finpharmanet-meeting-for-graduate-students/#
11:15 - 11:45 Challenges and opportunities for real-time release testing in continuous tablet manufacturing / Dr. Daniel Markl, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, UK
12:30 - 13:00 Developing a continuous drug substance manufacturing process / Dr. Cameron Brown, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, UK
Year(s) Of Engagement Activity 2021
URL https://nordicpop.ku.dk/events/kuopio-meeting-together-with-finpharmanet-meeting-for-graduate-studen...
 
Description 24 May 2017 , Pharmaceutical Online "Developing Mobile Continuous Process Technology: A Collaborative Innovation Case Study" . 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release about CMAC and REMEDIES project
Year(s) Of Engagement Activity 2017
URL https://www.pharmaceuticalonline.com/doc/developing-mobile-continuous-process-technology-a-collabora...
 
Description 26 January 2017 edition of Chemical Engineer Magazine "Continuous Collaboration" . 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Article in Chemical Engineer Magazine that outlines the CMAC activities including research, training, facilities and translation into industry.
Year(s) Of Engagement Activity 2017
URL https://www.thechemicalengineer.com/features/continuous-collaboration/
 
Description 28th November , featured in the Herald, "Alastair Florence: 'The key to success is working pre-competitively with industry' 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Article about CMAC in the Herald newspaper and online
Year(s) Of Engagement Activity 2017
URL http://www.heraldscotland.com/business_hq/15687920.Alastair_Florence___The_key_to_success_is_working...
 
Description 3rd ISCMP Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact The 3rd CMAC-MIT International Symposium on Continuous Manufacturing of Pharmaceuticals (ISCMP) brought together pharmaceutical company end users, suppliers, regulators and academics building on how research groups, globally, might collaborate more to help drive continuous manufacture and guide the way in which new technologies and approaches in the pharmaceutical industry can transform quality, cost and service for the benefit of the patient.

A key objective of the 2018 meeting was to address business, regulatory and technological barriers to increase the rate of integration of continuous manufacturing into process development. Thus, emphasis placed upon regulatory with modelling and process validation as high priority areas, in addition to business cases.

The London based event had excellent attendance across the board with 300 delegates and attracted many regulatory bodies including FDA, EMA and PMDA with Dr Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research delivering the keynote.

A key output from this is a White Paper, which will be published in the forthcoming year (2019/2020).
Year(s) Of Engagement Activity 2018
URL https://www.iscmp2018.org/
 
Description Accelerating the delivery of new drugs to patients 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact 25 June Accelerating the delivery of new drugs to patients - ARTICULAR announced.
Year(s) Of Engagement Activity 2018
URL https://www.strath.ac.uk/whystrathclyde/news/acceleratingthedeliveryofnewdrugstopatients/
 
Description Advanced Characterisation using Time of Flight Secondary Ion Mass Spectrometry (ToF-SIMS) Online Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact 21st May 2021 - half day online event co-organised by CMAC and NPL. Hub PI Prof Alastair Florence and CoI Prof Gavin Halbert were speakers
Year(s) Of Engagement Activity 2021
URL https://twitter.com/EPSRC_CMAC/status/1384778936291319811?cxt=HHwWhoCz4eHG3LcmAAAA
 
Description CMAC Open Day 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact The CMAC Open Day 2018 showcased the research outputs of the Future CMAC Hub through a packed programme of talks, posters, interactive demonstrations, a VR/AR demo and a tour that included a live demo of a prototype Lovastatin Microfactory and digital twin devloped as part of the CMAC Future Manufacturing research Hub research programme. Additionally, there were keynotes from Prof Marianthi Ierapetritou, Rutgers University and Prof Jon-Paul Sherlock, AstraZeneca and Chair of the CMAC Advisory Board. There were 260 delegates from 76 organisations in attendance including 22 exhibitors from technology companies.

All CMAC researchers presented a poster during the poster session.

The talks and posters related directly to the Lovastatin Microfactory and digital twin were:
Talks
Arjmandi-Tash, O.; Tew, J.D.; Yusoff, S.N.M.; Pitt, K.; Smith, R.; Litster, J. Mechanistic Modelling of Spherical Agglomeration. CMAC Open Day, Glasgow 25-26th October 2018
Brown, C.J.; Application of Process Models to Microfactories. CMAC Open Day 2018, Glasgow 25-26th October 2018
Hatcher, L. E.; Control of Lovastatin Crystal Shape and Size by Additive Crystallisation Methods CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018
Robertson, J.; Overview of CMAC Hub Microfactories. CMAC Open Day 2018, Glasgow 25-26th October 2018
Turner, T; The Intermolecular Synthon Analysis Associated with the Morphology and Surface Properties of the API Lovastatin. CMAC Open Day 2018, Glasgow 25-26th October 2018

Posters
Arjmandi-Tash, O.; Tew, J.D.; Yusoff, S.N.M.; Pitt, K.; Smith, R.; Litster, J. Mechanistic modelling of spherical agglomeration for continuous manufacturing of pharmaceuticals. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018
Hatcher, L. E.; Influence of Temperature and Additive Crystallisation Methods on Lovastatin Crystal Size and Shape; CMAC Open Day: University of Strathclyde, Glasgow, 25-26th October 2018
Jolliffe, H.G., Papathanasiou, F., Prasad E., Robertson J., Brown C.J., Halbert G., Florence A.J.; Predicting multi-component tablet properties from pure component parameters. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018
McGinty, J.; Developing a Workflow for Continuous Antisolvent Crystallisation. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018
Pallipurath, A.; Advanced Characterisation of Lovastatin: A Theoretical and Experimental Perspective. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018
Prasad, E.; Evaluation of gFormulate Modelling Tools for Tablet Compression. CMAC Open Day, University of Strathclyde, Glasgow, 25-26th October 2018
Robertson, M.; The CMAC Digital Platform. CMAC Open Day, University of Strathclyde, Glasgow, 25-26th October 2018
Tew, J.D.; Arjmandi-Tash, O.; Pitt, K.; Smith, R.; Litster, J. Wetting & Nucleation: Developing the Mechanistic Understanding of Spherical Agglomeration. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018
Vassileiou, A.; Using Machine Learning to Enhance Mechanistic Solubility Predictions. CMAC Open Day, University of Strathclyde, Glasgow, 25-26th October 2018
Watson, O. L.; Galindo, A.; Jackson, G.; Adjiman, C. S. Computer-aided design of solvent blends for the cooling and anti-solvent crystallisation of lovastatin and ibuprofen. CMAC Open Day, University of Strathclyde, Glasgow, 25-26th October 2018
Year(s) Of Engagement Activity 2018
 
Description CMAC PhD Mini-Symposia (Online) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A series of online mini-symposia were held in summer 2021 where CMAC PhD researchers presented their work to the CMAC Tier 1 partners.
Year(s) Of Engagement Activity 2021
 
Description CMAC REF 2021 Submission Published 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Jun 22, 2022: the REF2021 impact case study was published meaning we can now share CMAC's world leading submission - see https://results2021.ref.ac.uk/impact/fd8e9335-cb2e-44dc-b3af-85fe069ce2fe?page=2
£45 million in savings across
22 multinational and SME's for
??our research in #ContinuousManufacturing #Pharmaceuticals #Innovation
Year(s) Of Engagement Activity 2022
 
Description CMAC UK Showcase Event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact CMAC held a US Showcase for Tier 1s, Tier 2s and Hub academics, and members of the independent advisory board for the Hub at TIC, University of Strathclyde, Glasgow on 23rd October 2019. This aim of this event was to promote and widen engagement within the CMAC network by highlighting the broad range of activities taking place. The agenda included talks, Tier 1&2 Industry partner speed dating and an interactive Showcase of CMAC research. The CMAC research showcase covered 35 stations in 5 zones. Each station was either a live lab demo, an interactive demo of a model or digital tool or a poster. This allowed visitors to get a flavour of the braod research portfolio across CMAC, and talk with researchers about the work being showcased. Then there was a keynote and launch of white paper drafted as result of ISCMP 2018.
Year(s) Of Engagement Activity 2019
 
Description CMAC US Showcase, Boston 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact CMAC held a US Showcase for Partners - Industry Tier 1s, Industry Tier 2s and Hub academics at Takeda, Boston on 1st & 2nd May 2019. This aim of this event was to promote and widen engagement within the CMAC network by highlighting the broad range of activities taking place.
AZ, Eli Lilly, Pfizer and Takeda all presented on current status in Continuous Manufacture within their respective organisations and how this fits within their business plan. Nine Tier 2 companies attended, giving a snapshot of ongoing collaborations with CMAC which was very well received. Hub research updates were presented by academics across the CMAC network including Rachel Smith, Cameron Brown, John Robertson, Brahim Benyahia, Chris Price, Blair Johnston and Daniel Markl. The event concluded with a Keynote from Alastair Florence on, 'Transforming Medicines Development and Manufacture through Microfactories and Digital Twins'. The standard of all presentations was excellent, allowing the audience to see how the range of partners and activity in this area allows us to facilitate acceleration of our research efforts.
Year(s) Of Engagement Activity 2019
 
Description CMAC Virtual Open Day 2020 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact CMAC Virtual Open Day 2020 took place on the afternoons of 21-22nd Oct on the HopIn platform. The event this year was virtual due to COVID restrictions. We made the most of the opportunity to reach a wider international audience.
Number of delegates: we had 365 registrations, and around 180-190 people active in the platform at any one time during both days of the event.
Day 1 had talks from senior figures from the UK Medicines Manufacturing community and funders and a panel session.
11 Tier 2 exhibits: Anatune; Alconbury Weston Ltd.; Britest; CCDC; Clairet Scientific Ltd.; M-Star Simulations; Nitech Solutions Ltd.; Perceptive Engineering Ltd.; PSE; Technobis; and ThermoFisher.
The rest of the event disseminated recent CMAC research.
CMAC Talks:
1. Bresciani, M., Industrial Perspective, CMAC Virtual Open Day Oct 2020.
2. Brown, C., MicroFactory, CMAC Virtual Open day 2020.
3. Florence, A., CMAC Hub Update, CMAC Virtual Open Day 2020.
4. Johnston, B., Digital Platform, CMAC Virtual Open Day 2020.
5. Srai, J.S., Supply Chain, CMAC Virtual Open day 2020.
6. Schroeder, S., Know What You Don't Know: Process Design and Control of Product Attributes with Advanced X-ray Methods, CMAC Virtual Open Day, 2020.
7. Sharratt, P., Staying ahead of the game, CMAC Virtual Open Day 2020.
8. Smith, R., Digital Design Models, CMAC Virtual Open Day 2020.

Breakout Flash Presentations:
1. Ahmed, B., Spherical agglomeration: workflow development, CMAC Virtual Open Day, 21-22 Oct 2020.
2. Anandan, P., Controlling batch crystallisation process using reinforcement learning, CMAC Virtual Open Day, 21-22 Oct 2020.
3. Bernet, T., Hands-on software demonstration of solubility calculations with SAFT-? Mie including mixed solvents and impurities, CMAC Virtual Open Day, 21-22 Oct 2020.
4. Brown, C., Digital design of end-to-end manufacturing process for Mefenamic Acid, CMAC Virtual Open Day, 21-22 Oct 2020.
5. Chong, M., Aligning measurements with the QbDD approach, CMAC Virtual Open Day, 21-22 Oct 2020.
6. Doerr, F., Small-scale parameter estimation on Crystalline through image analysis and translation to PBE model including error propagation for 1st crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020.
7. Jolliffe, H., Medicines Manufacturing Innovation Centre (MMIC): the use of a Digital Twin, CMAC Virtual Open Day, 21-22 Oct 2020.
8. Kathyola, T., Multi-scale understanding of Lovastatin crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020.
9. Li, W., Continuous crystallisation development from batch experimental data to modelling of kinetics estimation/optimisation to experimental validation for second crystallisation., CMAC Virtual Open Day, 21-22 Oct 2020.
10. Marce Villa, P., Feasibility workflow: integration of continuous synthesis and crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020.
11. McGinty, J., Developing a workflow for continuous antisolvent crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020.
12. Mendez, C., Development of methods to assess mixing efficiency in commercial tablet manufacture, CMAC Virtual Open Day, 21-22 Oct 2020.
13. Ojo, E., Towards the prediction of direct-compaction of multicomponent drug product formulation, CMAC Virtual Open Day, 21-22 Oct 2020.
14. Ottoboni, S., Model based design and optimisation: filtration and washing parameters estimation and strategies implementation. Linking crystallisations through isolatio, CMAC Virtual Open Day, 21-22 Oct 2020.
15. Ottoboni, S., Novel rational approach to design purification solvent selection based on isolation: workflow approach assisted by predictive and modelling tools, CMAC Virtual Open Day, 21-22 Oct 2020.
16. Pallipurath, A., Towards rational design and control of crystallisation processes, CMAC Virtual Open Day, 21-22 Oct 2020.
17. Portela, V., An immersive training environment for the assembly of an EasyMax chemical stirrer, CMAC Virtual Open Day, 21-22 Oct 2020
18. Prakash, A., ToF-SIMS in pharmaceutical manufacturing, CMAC Virtual Open Day, 21-22 Oct 2020.
19. Prasad, E., Improving consistency for a Mefenamic acid immediate release formulation, CMAC Virtual Open Day, 21-22 Oct 2020.
20. Rajoub, N., Spherical agglomeration: workflow development, CMAC Virtual Open Day, 21-22 Oct 2020.
21. Robertson, M., Exploring the CMAC data strategy: digital workflows and risk mapping, CMAC Virtual Open Day, 21-22 Oct 2020.
22. Settanni, E., MicroFactory supply chain design, CMAC Virtual Open Day, 21-22 Oct 2020.
23. Srirambhatla, V., Machine learning approaches to predict glass forming ability and morphology of pharmaceutical compounds, CMAC Virtual Open Day, 21-22 Oct 2020.
24. Vassileiou, A., Combined AI techniques for particle sizing directly from microscope images, CMAC Virtual Open Day, 21-22 Oct 2020.
25. Vassileiou, A., Solubility prediction by machine learning and a survey of solvates in the CSD, CMAC Virtual Open Day, 21-22 Oct 2020.
26. Warzecha, M., Understanding the adsorption of impurities on crystal faces using molecular modelling and atomic force microscopy, CMAC Virtual Open Day, 21-22 Oct 2020.
27. Watson, O., Demonstrating the selection of optimal solvent mixtures for the crystallisation of APIs in gPROMS/gSAFT, CMAC Virtual Open Day, 21-22 Oct 2020.
30. Willneff, E., Linking molecule to product with environmental X-ray Photoelectron Spectroscopy, CMAC Virtual Open Day, 21-22 Oct 2020.

Posters:
1. Abdallah, N., In situ monitoring of the cooling crystallisation of mefenamic acid using Raman, Terahertz-Raman and ATR-UV spectroscopies, CMAC Virtual Open Day, 21-22 Oct 2020.
2. Ahmed, B., Spherical agglomeration: workflow development, CMAC Virtual Open Day, 21-22 Oct 2020.
3. Alsuleman, M., Material based decision for formulating a 3D printing filament, CMAC Virtual Open Day, 21-22 Oct 2020.
4. Anandan, P., Controlling batch crystallisation process using reinforcement learning, CMAC Virtual Open Day, 21-22 Oct 2020.
5. Bernet, T., SAFT-? Mie modelling of groups and complex molecules; parameter estimation framework and performance, CMAC Virtual Open Day, 21-22 Oct 2020.
6. Blazejczak, M., MMIC: Developing next-generation pharmaceutical manufacturing, CMAC Virtual Open Day, 21-22 Oct 2020.
7. Bordos, E., Effect of material and process parameters on the microstructure of amorphous solid dispersions, CMAC Virtual Open Day, 21-22 Oct 2020.
8. Cashmore, A., A rapid and small-scale assessment of secondary nucleation and growth kinetics of ?-glycine, CMAC Virtual Open Day, 21-22 Oct 2020.
9. Chong, M., Temperature correction of UV spectra for improved concentration monitoring during cooling crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020.
10. Creswick, J., Analysis of novel spherical agglomerate tablets: fragmentation quantification and impact on tablet performance, CMAC Virtual Open Day, 21-22 Oct 2020.
11. Das, G., Time-resolved microfocus synchrotron X-ray Phase Contrast Imaging (XPCI) - a versatile tool for predictive design and control of crystallisation processes, CMAC Virtual Open Day, 21-22 Oct 2020.
12. Devlin, M., Structure and transformations in amorphous Paracetamol, CMAC Virtual Open Day, 21-22 Oct 2020.
13. Doerr, F., Model-based design and optimisation of crystallisation processes: image analysis methodologies for small scale parameter estimation, CMAC Virtual Open Day, 21-22 Oct 2020.
14. Eales, W., Measuring and modelling agglomeration and breakage during agitated vacuum thermal drying, CMAC Virtual Open Day, 21-22 Oct 2020.
15. Flannigan, J., An investigation of secondary nucleation at the microscale using optical tweezing, CMAC Virtual Open Day, 21-22 Oct 2020.
16. Hou, P., Design of a micro-feeder for solid pharmaceuticals, CMAC Virtual Open Day, 21-22 Oct 2020.
17. Johnston, J., Model-driven controller design for continuous crystallisation of ?-Lactose Monohydrate, CMAC Virtual Open Day, 21-22 Oct 2020.
18. Jolliffe, H., Medicines Manufacturing Innovation Centre (MMIC): the use of a Digital Twin, CMAC Virtual Open Day, 21-22 Oct 2020.
19. Jonuzaj, S., Solvent mixture design and optimisation for the integrated crystallisation and isolation of Mefenamic Acid, CMAC Virtual Open Day, 21-22 Oct 2020.
20. Kathyola, T., X-ray scattering and X-ray Photoelectron Spectroscopy analysis of Mefenamic Acid thermal-induced polymorphism, CMAC Virtual Open Day, 21-22 Oct 2020.
21. Kitching, V., The influence of vessel and agitator geometry and speed on flow characteristics in spherical agglomerators, CMAC Virtual Open Day, 21-22 Oct 2020.
22. Li, W., Model-based design and optimization of multistage mixed suspension mixed product removal crystallization of Mefenamic Acid, CMAC Virtual Open Day, 21-22 Oct 2020.
23. Mack, C., Thermodynamics in Antisolvent Phase Diagrams: Methodology Development and Molecular Interactions, CMAC Virtual Open Day, 21-22 Oct 2020.
24. Mahon, J., Investigating structural changes of amorphous solid dispersions during dissolution, CMAC Virtual Open Day, 21-22 Oct 2020.
25. Marce Villa, P., Feasibility workflow: integration of continuous synthesis and crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020.
26. McGinty, J., Developing a workflow for continuous antisolvent crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020.
27. McKechnie, D., Tuning dispersion interactions to control heterogeneous nucleation, CMAC Virtual Open Day, 21-22 Oct 2020.
28. Mendez, C., Development of methods to assess mixing efficiency in commercial tablet manufacture, CMAC Virtual Open Day, 21-22 Oct 2020.
29. Miller, R., Modelling diffusive mixing in continuous antisolvent crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020.
30. Mnemo, M., Digital design strategies for industrial crystallisation development, CMAC Virtual Open Day, 21-22 Oct 2020.
31. Murphy, K., Analysis of terahertz scattering of granular materials, CMAC Virtual Open Day, 21-22 Oct 2020.
32. Nakapraves, S., Machine learning approaches for predictive design of the crystal shape of Mefenamic Acid, CMAC Virtual Open Day, 21-22 Oct 2020.
33. Ojo, E., Multistage, multi-zones antisolvent-cooling crystallisation of a proprietary API: Experimental comparison of effect of geometry and hydrodynamics in four batch crystallisers, CMAC Virtual Open Day, 21-22 Oct 2020.
34. Ottoboni, S., Understanding API static drying with hot gas flow: design and test of a drying rig prototype and drying modelling development, CMAC Virtual Open Day, 21-22 Oct 2020.
35. Pallipurath, A., Towards rational design and control of crystallisation processes, CMAC Virtual Open Day, 21-22 Oct 2020.
36. Pallipurath, A. R., Insights into thermodynamic solution properties from X-ray Pair Distribution Function analysis, CMAC Virtual Open Day, 21-22 Oct 2020.
37. Payne, P., Benchmarking the CMAC additive and multicomponent screening workflows, CMAC Virtual Open Day, 21-22 Oct 2020.
38. Pereira-Diaz, L., Coupling primary and secondary manufacturing via digital design of crystalline materials, CMAC Virtual Open Day, 21-22 Oct 2020.
39. Portela, V., An immersive training environment for the assembly of an EasyMax chemical stirrer, CMAC Virtual Open Day, 21-22 Oct 2020.
40. Powell, D., Protein Nucleation in microfluidic devices, CMAC Virtual Open Day, 21-22 Oct 2020.
41. Prakash, A., ToF-SIMS in pharmaceutical manufacturing, CMAC Virtual Open Day, 21-22 Oct 2020. 2020.
42. Prasad, E., Improving consistency for a Mefenamic acid immediate release formulation, CMAC Virtual Open Day, 21-22 Oct 2020.
43. Prostredny, M., MMIC Grand Challenge 1: Process equipment and facilities, CMAC Virtual Open Day, 21-22 Oct 2020.
44. Robertson, M., Exploring the CMAC data strategy: digital workflows and risk mapping, CMAC Virtual Open Day, 21-22 Oct 2020.
45. Sanxaridou, G., Mechanical properties of agglomerates produced by two different drying methods, CMAC Virtual Open Day, 21-22 Oct 2020.
46. Settanni, E., MicroFactory supply chain design, CMAC Virtual Open Day, 21-22 Oct 2020.
47. Shahid, M., Employing constant rate filtration to improve active pharmaceutical ingredients (APIs) washing efficiency, CMAC Virtual Open Day, 21-22 Oct 2020.
48. Siddique, M., Quantification of granule formation during drying as a function of solubility in residual solvents, CMAC Virtual Open Day, 21-22 Oct 2020.
49. Smith, K., CMAC National Facility short case studies, CMAC Virtual Open Day, 21-22 Oct 2020.
50. Soundaranathan, M., Quantification of swelling characteristics of pharmaceutical particles, CMAC Virtual Open Day, 21-22 Oct 2020.
51. Srirambhatla, V., Machine learning approach for the prediction of glass-forming ability of pharmaceutical compounds, CMAC Virtual Open Day, 21-22 Oct 2020.
52. Straughair, L., Analysis of organic crystals containing solvents in the CSD, CMAC Virtual Open Day, 21-22 Oct 2020.
53. Tew, J., A mechanistic study of wetting & nucleation in spherical agglomeration, CMAC Virtual Open Day, 21-22 Oct 2020.
54. Totten, J., Impact of silk stock on nanoparticle assembly and characteristics, CMAC Virtual Open Day, 21-22 Oct 2020.
55. Vassileiou, A., Combined AI techniques for particle sizing directly from microscope images, CMAC Virtual Open Day, 21-22 Oct 2020.
56. Vassileiou, A., Solubility prediction by machine learning and a survey of solvates in the CSD, CMAC Virtual Open Day, 21-22 Oct 2020.
57. Vivattanaseth, P., In situ monitoring of hot melt extrusion with Terahertz (THz) - Raman spectroscopy, CMAC Virtual Open Day, 21-22 Oct 2020.
58. Walsh, E., Manufacturing tablets with desired specific surface area, CMAC Virtual Open Day, 21-22 Oct 2020.
59. Ward, M., Recovery of high-pressure solid forms to ambient pressures, CMAC Virtual Open Day, 21-22 Oct 2020.
60. Warzecha, M., Understanding the adsorption of impurities on crystal faces using molecular modelling and atomic force microscopy, CMAC Virtual Open Day, 21-22 Oct 2020.
61. Watson, O., Computer-aided solvent selection for the control of crystal morphology of pharmaceutical compounds, CMAC Virtual Open Day, 21-22 Oct 2020.
62. Wilkinson, M., Applying machine learning to the prediction of crystal morphology, CMAC Virtual Open Day, 21-22 Oct 2020.
Year(s) Of Engagement Activity 2020
 
Description CMAC X-ray youtube channel 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact CMAC X-ray youtube channel
3 videos added: Pound coin CT, Paracetamol capsule analysis, Tablet coating analysis
https://www.youtube.com/channel/UCNWMxJQVvxmn_VynR53fIYA
Year(s) Of Engagement Activity 2019
URL https://www.youtube.com/channel/UCNWMxJQVvxmn_VynR53fIYA
 
Description CMAC contribution to UKRI #EPSRCBuildingResilience: Sustainable, cost-effective medicine manufacturing 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Video case study was published by UKRI, CMAC Director and Hub PI, Prof Alastair Florence was interviewed, and filming done at the CMAC National Facility in TIC, University of Strathclyde. It describes the benefits of digital twins in medicines manufacturing, and shows the equipment being used in the labs by the Hub team and the digital twin graphics.
Year(s) Of Engagement Activity 2021
URL https://www.youtube.com/watch?v=ix6rP6_QnZY
 
Description CMAC was an exhibitor at the Scottish Science Advisory Council (SSAC) Reception Jan 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Policymakers/politicians
Results and Impact CMAC was an exhibitor at the Scottish Science Advisory Council (SSAC) reception on Wednesday 23rd January 2019 at Dynamic Earth in Edinburgh for the launch of Science landscape report. Both the full report and summary can be found on the SSAC website at:- http://www.scottishscience.org.uk/publications
Industry Director Craig Johnston met with the Scottish Minister for Higher Education & Science, Richard Lochhead.
Year(s) Of Engagement Activity 2019
 
Description Cambridge Crystallographic Data Centre (CCDC) has joined CMAC as a Tier 2 Member 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact 23 October Cambridge Crystallographic Data Centre (CCDC) has joined CMAC as a Tier 2 Member.
Year(s) Of Engagement Activity 2018
URL https://www.ccdc.cam.ac.uk/News/List/2018-10-23-ccdc-joins-future-manufacturing-initiative-to-help/
 
Description Chemical Engineer Article May 2018 "Continuous crystallisation workflow enables high precision manufacturing of pharmaceuticals" 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 09 May Chemical Engineer Article May 2018 "Continuous crystallisation workflow enables high precision manufacturing of pharmaceuticals" link below. Features C J Brown et al, Mol. Syst. Des. Eng., 2018, DOI: 10.1039/c7me00096k
Year(s) Of Engagement Activity 2018
URL https://www.thechemicalengineer.com/news/continuous-crystallisation-workflow-enables-high-precision-...
 
Description Chemistry World "The Case for Lab Management Systems" 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 03 July edition of Chemistry World "The Case for Lab Management Systems"
Year(s) Of Engagement Activity 2018
URL https://www.chemistryworld.com/opinion/the-case-for-lab-management-systems/3009220.article
 
Description Chemistry World Article March 2018 "Solving the Crystal Maze" by Laura Fisher 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 26 March Chemistry World Article March 2018 "Solving the Crystal Maze" by Laura Fisher (26th March 2018) link below (subscribers only). Highlights the CMAC publication C J Brown et al, Mol. Syst. Des. Eng., 2018, DOI: 10.1039/c7me00096k
Year(s) Of Engagement Activity 2018
URL https://www.chemistryworld.com/news/solving-the-crystal-maze/3008812.article
 
Description Continuous manufacturing: making it real: 24th April 2019, Manufacturing Chemist 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact "Continuous manufacturing: making it real" 24th April 2019, Dr Kevin Robertson, Manufacturing Chemist https://www.manufacturingchemist.com/news/article_page/Continuous_pharma_manufacturing_making_it_real/154030

Prof. Alastair Florence, Director of the EPSRC Future Manufacturing Research Hub, Continuous Manufacturing and Advanced Crystallisation (CMAC), noted the use of continuous processes to improve both scale-down as well as scale-up, promoting miniaturisation to accelerate product development with less (valuable) API.
Year(s) Of Engagement Activity 2019
URL https://www.manufacturingchemist.com/news/article_page/Continuous_pharma_manufacturing_making_it_rea...
 
Description Doors Open Glasgow 2022 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact CMAC are participated in the #Glasgow Doors Open Days Festival (https://glasgowdoorsopendays.org.uk) Saturday 17th September 2022 (10am-4pm) at the Technology & Innovation Centre (TIC), University of Strathclyde.
Year(s) Of Engagement Activity 2022
URL https://glasgowdoorsopendays.org.uk/building-no-booking/technology-innovation-centre-tic-university-...
 
Description EPSRC 's Executive Chair, Lynn Gladden visit & blog mention 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact In a new blog post, the EPSRC 's Executive Chair, Lynn Gladden, reflects on her university visits, including a visit to CMAC at University of Strathclyde. It was a pleasure to host Lynn as part of this tour, showcasing our facilities and discussing how CMAC can work with UKRI to 'transform tomorrow together'.
Year(s) Of Engagement Activity 2022
URL https://bit.ly/3Du7kgM
 
Description Harriet Wallace, Director for International Research and Innovation, visits CMAC in TIC 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Harriet Wallace, Director for International Research and Innovation, @beisgovuk visited University of Strathclyde and visited CMAC for a tour of our facilities and to discuss our research in pharmaceutical manufacturing.
Year(s) Of Engagement Activity 2021
URL https://twitter.com/EPSRC_CMAC/status/1435218322866454529?cxt=HHwWgoCy2bzd9eonAAAA
 
Description Hosted visitors from Bristol Myers Squibb & Malvern Panalytical 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact CMAC were delighted to host visitors from Bristol Myers Squibb & Malvern Panalytical @newsfrom_MP 17th Aug 2022. Mike Tobyn (Senior Scientific Director at Bristol-Myers Squibb) gave an engaging seminar to the CMAC community titled Small Particles and Big Data.
Year(s) Of Engagement Activity 2022
 
Description Huxley Bertram Press Release Nov 2020 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact The announcement of Huxley Bertram as Tier 2 Partner in CMAC.
CMAC are pleased to announce that following the recent establishment of our new Compaction Simulation Pilot Test Facility that we can now offer Compaction Simulation Research Services through our National Facility Team. This is supported by a new partnership between Huxley Bertram and the CMAC Future Manufacturing Research Hub at the University of Strathclyde (Glasgow, UK). An HB50 Huxley Bertram Compaction Simulator specified with instrumented dies and innovative process analytics for in situ measurements using terahertz spectroscopy has recently been installed in CMAC's facilities. Compaction simulation research at CMAC is being led by academics and scientists expert in compaction simulation with cutting edge application and engineering support provided by Huxley Bertram's Cambridge-based staff.

CMAC National Research Facility was established through investment from UK-RPIF, Wolfson Foundation, SFC, University of Strathclyde and our industry partners and is the only international academic facility to receive a coveted ISPE 'Facility of the Year Award'. The first in world integrated compaction simulator-terahertz system was made possible by support from EPSRC which is housed alongside suites of state-of-the-art continuous processing equipment, extensive process analytics, advanced automation & control and advanced characterisation techniques for pharmaceutical systems. The facility has a dedicated support team which offers consultancy, research services and collaboration support for both academic & industrial research & development.

Compaction Simulation Services

Several levels of compaction simulation research and development work are available on a contract basis:
Material characterisation and advanced compaction studies of active pharmaceutical ingredients (APIs), excipients and blends.
Routine powder characterisation, constitutive analyses (axial stress/strain).
Compactibility/compressibility/tabletability studies.
Radial analyses (instrumented dies).
Advanced compaction studies: radial analyses, frictionless ejection.
Die compaction (rotary press) roll compaction and capsule tamping.
High-fidelity rotary presses simulation, including hybrid MODUL simulations.
Material-sparing formulation and process development.
Material-sparing replication of direct compression & dry granulation processes (DC/DG).
Formulation assistance and optimisation including lubrication studies.
Formulation design, development and scale-up.
Process understanding development:
Compaction understanding and materials science by pairing compaction simulation with exceptional advanced characterisation techniques: X-ray computed nanotomography, time-of-flight secondary ion mass spectrometry, etc.
Compaction thermodynamics, in-die temperature evolution.
Microstructure analysis using terahertz spectroscopy and X-ray computed nanotomography.
Troubleshooting of clinical and commercial die compaction processes

Contact us for more information
CMAC Future Manufacturing Research Hub: Claire MacDonald, claire.macdonald.101@strath.ac.uk
For other simulation services inquiries contact Huxley Bertram: Martin Bennett, martinwbennett@huxleybertram.com
Year(s) Of Engagement Activity 2020
URL https://www.cmac.ac.uk/showNews.php
 
Description Looking back to look forward 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact 22 June Looking back to look forward - ReMEDiES article.
Year(s) Of Engagement Activity 2018
URL https://remediesproject.com/2018/04/16/looking-back-to-look-forward-craig-johnston/
 
Description MMIP working group - skills 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Medicines Manufacturing Industry Partnership skills working group conducted questionnaire to assess the needs of future skillforce. This has fed directly into the Office of Life Sciences SKill Strategy 2030. Report has been launched and disseminated across governement, industry profeesionals and leading academics as well as funding bodies.
Year(s) Of Engagement Activity 2018,2019,2020
URL https://www.scienceindustrypartnership.com/skills-issues/sip-2030-skills-strategy/
 
Description Microfactory and Digital Twin Video 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact 24 October EPSRC CMAC Future Manufacturing Research Hub - Microfactory and Digital Twin video.
Year(s) Of Engagement Activity 2018
URL https://www.youtube.com/watch?v=MttQ-nAs3VM
 
Description New CMAC Industry Board Chair - Dr Ivan Marziano 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact CMAC announced the new chair of the CMAC Industry Board by press release on the CMAC website and Twitter.
Year(s) Of Engagement Activity 2022
URL https://cmac.ac.uk/news-database/a-new-chapter-for-cmacs-industry-board
 
Description Panel at Pharma Integrates 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Panel: Digitally Enabling Technologies for Continuous Manufacture and Regulatory Needs: Pharma Integrates 2018 (Day 2)
Facilitated by: Craig Johnston Industry Director, CMAC.
Video of panel https://www.lifescienceintegrates.com/videos-for-pharma-2018/
Year(s) Of Engagement Activity 2018
URL https://www.lifescienceintegrates.com/videos-for-pharma-2018/
 
Description Parliamentary Under Secretary of State visits CMAC Facilities in TIC 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Policymakers/politicians
Results and Impact Paul Scully MP, Parliamentary Under Secretary of State (Minister for Small Business, Consumers and Labour Markets) visited the CMAC National Facility in in the Technology and Innovation Centre at University of Strathlcyde during w/c 15th Feb 2022.
Year(s) Of Engagement Activity 2022
URL https://twitter.com/EPSRC_CMAC/status/1494276562245533697?cxt=HHwWgoCyjbmn3rwpAAAA
 
Description Pharma Sustainability Integrates 2022 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact CMAC CoI Prof Chris Price presented at this event which was co-organised by MMIC partners. His talk was Manufacturing showcase: A presentation on achieving sustainable pharmaceutical manufacturing
Year(s) Of Engagement Activity 2022
URL https://www.lifescienceintegrates.com/pharma-sustainability-integrates-agenda-2022/
 
Description PharmaTech Integrates 2021 - CMAC Contribution 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact PharmaTech Integrates - https://www.lifescienceintegrates.com/pharmatech-integrates-2021/ -
CMAC were an exhibitor.
MASSIMO BRESCIANI, Industry Director, EPSRC Future Manufacturing Research Hub, CMAC was on Organising Committee.
Technology Showcase CMAC: Digital Twins and MicroFactories. Directors, Prof Alastair Florence and Massimo Bresciani, presented on how CMAC are working on flexible integrated manufacturing technologies to accelerate product and process development, providing greater agility, sustainability and flexibility for future medicines development and manufacture.
Session: Making solid progress in Continuous Direct Compression - ALASTAIR FLORENCE | Director, Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub | University of Strathclyde was a panelist
Year(s) Of Engagement Activity 2021
URL https://www.lifescienceintegrates.com/pharmatech-integrates-2021/
 
Description Press Release - Laminar and UK/IRE Distributor Analytik Join CMAC - Dec 2020 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Continuous flow chemical reactor manufacturer Laminar Co Ltd (Jungwon-gu, Republic of Korea), represented in the UK and Ireland by Analytik Ltd (Cambridge, UK), have joined the CMAC Future Manufacturing Research Hub as tier 2 members from October 2020.

Laminar manufactures the world's first commercially available chemical reactors which utilise Taylor Fluid Flow to synthesize high-purity, uniform substances. The patented design chemical reactors use a jacketed cylindrical vessel with a central, rotating agitation bar to produce Taylor Flow mixing along the length of the vessel resulting in 3-times faster mass flow transfer compared to tank type reactors.

The partnership will see the first Taylor Flow Reactor installed in the UK at CMAC's Technology Innovation Centre (TIC) site in Glasgow, which will initially be studied to greater understand the mechanisms and potential of the technology, explore new syntheses and be benchmarked against existing processes. The CMAC Future Manufacturing Research Hub brings together a research team at Strathclyde, as well as other leading academic groups and an array of industry partners to address the urgent need to translate new molecules into high-value products through rapid predictive development pathways and integrated continuous manufacturing systems.

Analytik announced a partnership with Laminar to distribute their Taylor Flow Reactors in the UK and Ireland in 2019. Specialists in providing and supporting pioneering technology, it will oversee the installation of a Tera3100-HC Laminar Continuous Taylor Reactor (LCTR®) at CMAC in early 2021, as well as provide ongoing technical and service support over 3 years.

Speaking about the membership, Ian Laidlaw, Managing Director at Analytik said "We are delighted to be joining the CMAC Future Manufacturing Research Hub and excited to be facilitating the first LCTR® chemical reactor installation in the UK. This fantastic technology sets a new standard for high yield synthesis of high-purity, uniform substances and offers faster, more efficient continuous processing".

Professor Alastair Florence, Director of CMAC added "It is a pleasure to welcome Laminar and Analytik to CMAC's community. This partnership brings exciting new opportunities for our research team to work with this unique Taylor Flow Reactor platform to explore the potential for this advanced technology across reaction, work-up, purification and particle engineering for pharmaceutical systems. This technology will extend our Digital Twin and MicroFactory platforms for continuous manufacturing and create real benefits and impacts to our stakeholders though enabling faster process and product development and reducing the cost and environmental impact of medicines manufacture."

You can find out more about Laminar Continuous Taylor Reactors (LCTR) by visiting the Analytik website: https://analytik.co.uk/product/continuous-flow-reactor/.
Year(s) Of Engagement Activity 2020
URL https://www.cmac.ac.uk/showNews.php
 
Description Queen's Anniversary Prize 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact CMAC were honoured to be part of the University of Strathclyde's team that received the Queen's Anniversary Prize for Higher and Further Education at St James's Palace on 23rd Feb 2022 for our excellence in Advanced Manufacturing. The university and CMAC have posted this on their websites.
Year(s) Of Engagement Activity 2022
URL https://cmac.squarespace.com/news-database/qap
 
Description Robotics Fair at Strathclyde 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Jan 25 2023: CMAC researchers Chantal Mustoe and Faisal Abbas took part in a Robotics Industry Fair at the University of Strathclyde. This was a great opportunity to showcase their work with robotics as part of our DataFactories and Digital Medicines Manufacturing programmes.
Year(s) Of Engagement Activity 2023
 
Description Science and Technology Committee visit to CMAC Facilities in TIC 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Visitors from the Science and Technology Committee visited the CMAC National Facility as part of a visit to University of Strathclyde on 11th Feb 2022.
Year(s) Of Engagement Activity 2022
URL https://twitter.com/CommonsSTC/status/1492181799522418692?cxt=HHwWiICyzZrcpbUpAAAA
 
Description Scotland House Office Opens 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact CMAC are take up residence at Scotland House, London, UK on 29/04/2022. We're delighted to introduce the new CMAC Central London Office. Press release on website.
Year(s) Of Engagement Activity 2022
URL https://cmac.ac.uk/news-database/cmac-london-office
 
Description Scottish Secretary of State visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Policymakers/politicians
Results and Impact CMAC were happy to show Scottish Secretary of State, Lord Offord of Garvel, around our world-leading facilities at the end of July 2022 as part of his broader visit to University of Strathclyde.
Year(s) Of Engagement Activity 2022
 
Description Siemens released a video of Alwyn Jones, Siemens UK & Ireland Head of Pharmaceutical & Life Sciences, in conversation with CMAC's Industry Director Craig Johnston 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact 26 February Siemens released a video of Alwyn Jones, Siemens UK & Ireland Head of Pharmaceutical & Life Sciences, in conversation with CMAC's Industry Director Craig Johnston
Year(s) Of Engagement Activity 2018
URL https://www.youtube.com/watch?v=kbzSgHFn_w4&__prclt=DZb25HTl
 
Description Strathclyde in Medicines Manufacturing Innovation Centre - press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact 15 June Strathclyde in Medicines Manufacturing Innovation Centre Full press release link below.
Year(s) Of Engagement Activity 2018
URL https://www.strath.ac.uk/whystrathclyde/news/strathclydeinmedicinesmanufacturinginnovationcentre/
 
Description Talk by Dr Jag Srai (CoI): Building Back Better: harnessing technology to create new products, markets and business models 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact 25th International Manufacturing Symposium (Online) - https://cimsymposium.eng.cam.ac.uk/2021programme.
Talk: Building Back Better: harnessing technology to create new products, markets and business models. Speakers: Nitin Joglekar (Boston University, USA); Geoff Parker (Dartmouth/MIT, USA); Jag Srai (Cambridge University)
Year(s) Of Engagement Activity 2021
URL https://cimsymposium.eng.cam.ac.uk/2021programme
 
Description UK Manufacturing Outlook 2022 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact CMAC Future Manufacturing Research Hub is featured in UK Manufacturing Outlook 2022. Tweet from UK Manufacturing Outlook 2022: @ukmfgoutlook·Jun 9, 2022: UK's #Medicines #manufacturing exports >£25bn, has the highest GVA of any sector (£8.5bn) & invests >£4bn pa on R&D. The CMAC Future Manufacturing Research Hub is developing more efficient, responsive & resilient processes for a market projected to grow 3-6%pa to £1.2tr by 2025.
Year(s) Of Engagement Activity 2022
URL https://uk-mo.com/technologies/transforming-medicines-manufacturing
 
Description Video of talk "Supercritical CO2 Drying End-Point by Using SIFT-MS Analysis" 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Video of talk "Supercritical CO2 Drying End-Point by Using SIFT-MS Analysis" by CMAC PhD Georgia Sanxaridou (Dr Chris Price's group at University of Strathclyde) at The SIFT-MS Interest Group Meeting 2019.
Here is the link
https://www.youtube.com/watch?v=XoOMgv1unQU&list=PL3J3TYiNeMFpBFzXYoY5JcFItH93rvflh?dex=4&t=0s
Year(s) Of Engagement Activity 2019
URL https://www.youtube.com/watch?v=XoOMgv1unQU&list=PL3J3TYiNeMFpBFzXYoY5JcFItH93rvflh&index=4&t=0s
 
Description Visit by MP Carol Monaghan 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Policymakers/politicians
Results and Impact CMAC hosted MP Carol Monaghan on 5th October 2022 (@CMonaghanSNP) and showcased all the innovative medicines manufacturing research being carried out by CMAC here in Glasgow.
Year(s) Of Engagement Activity 2022
 
Description Visit by Parliamentary Under Secretary of State (Minister for Small Business, Consumers and Labour Markets) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Policymakers/politicians
Results and Impact 17/02/2022: CMAC host UK were thrilled to host Parliamentary Under Secretary of State (Minister for Small Business, Consumers and Labour Markets), @scullyp this week and provide a tour of our facilities highlighting #CMACs vision to transform #medicines development, manufacture and supply.
Year(s) Of Engagement Activity 2022
 
Description Visit by UK Science and Technology Select Committee 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Policymakers/politicians
Results and Impact 11/02/2022: CMAC were delighted to host the UK Science and Technology Select Committee this week! We were excited to provide its members with a guided tour of our #facilities and show how #CMAC are helping tackle major UK and global challenges in #medicinesmanufacturing. #researchexcellence
Year(s) Of Engagement Activity 2022
 
Description Webinar on the #FutureOfWork in Medicines #Manufacturing 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact @ESRC @InterActNetw0rk collaborated with CMAC to host a webinar on the #FutureOfWork in Medicines #Manufacturing, Thursday 12 January, 2023. Traget audience members: people manager or workplace stakeholder in the sector.
Year(s) Of Engagement Activity 2023
URL https://linkedin.com/pulse/digital-medicines-manufacturing-future-work-webinar-lindsay-mcipd-/